ADMA vs GRFS vs TAK vs CSL vs BIO

For growth investors, ADMA Biologics, Inc.

(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 1x trailing P/E (27. 4x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 1x versus Takeda Pharmaceutical Company Limited at 76. 8x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Carlisle Companies Incorporated's 0. 71x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +389. 2%, compared to -57. 9% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: CSL returned +277. 3% versus GRFS's -35. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus ADMA Biologics, Inc. 's 1. 25β — meaning ADMA is approximately 281% more volatile than TAK relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 160% for Carlisle Companies Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADMA Biologics, Inc.

(ADMA) is pulling ahead at 19. 6% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -38. 6% for Carlisle Companies Incorporated. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 7. 5% for TAK. At the gross margin level — before operating expenses — TAK leads at 65. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Carlisle Companies Incorporated's 0. 71x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 27. 4x for Bio-Rad Laboratories, Inc. — 27. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 157. 0% to $21. 00.

In this comparison, TAK (3.

6% yield), GRFS (2. 6% yield), CSL (1. 2% yield) pay a dividend. ADMA, BIO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

33), 3. 6% yield). Both have compounded well over 10 years (TAK: -2. 1%, ADMA: +34. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ADMA (Healthcare) and GRFS (Healthcare) and TAK (Healthcare) and CSL (Industrials) and BIO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; TAK is a mid-cap income-oriented stock; CSL is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock. GRFS, TAK, CSL pay a dividend while ADMA, BIO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.